Search


Start a new search
Add filters:

Use filters to refine the search results.


Results 89101-89110 of 90919 (Search time: 0.039 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2007Successful microsurgical penile replantation after a workplace injuryFuller, A.; Bolt, J.; Carney, B.
2013Misdiagnosis of orthokeratology-related Acanthamoeba keratitis as herpes simplex virus keratitisGreenwell, T.; Loh, R.; Chehade, M.; Mills, R.
2008Long-term imatinib therapy promotes bone formation in CML patientsFitter, S.; Dewar, A.; Kostakis, P.; To, L.; Hughes, T.; Roberts, M.; Lynch, K.; Vernon-Roberts, B.; Zannettino, A.
2018Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicityStansborough, R.; Bateman, E.; Al-Dasooqi, N.; Bowen, J.; Wignall, A.; Keefe, D.; Yeoh, A.; Logan, R.; Yeoh, E.; Stringer, A.; Gibson, R.
2010The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivoVandyke, K.; Dewar, A.; Diamond, P.; Fitter, S.; Schultz, C.; Sims, N.; Zannettino, A.
2010Dysregulation of bone remodeling by imatinib mesylateVandyke, K.; Fitter, S.; Dewar, A.; Hughes, T.; Zannettino, A.
2006Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myelomaMartin, S.; Dewar, A.; Farrugia, A.; Horvath, N.; Gronthos, S.; To, L.; Zannettino, A.
2005Inhibition of c-fms by imatinib - Expanding the spectrum of treatmentDewar, A.; Zannettino, A.; Hughes, T.; Lyons, A.
2009Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesisVandyke, K.; Dewar, A.; Farrugia, A.; Fitter, S.; To, B.; Hughes, T.; Zannettino, A.
2005Imatinib inhibits the functional capacity of cultured human monocytesDewar, A.; Doherty, K.; Hughes, T.; Lyons, A.